Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

• Published in: Blood Vol. 142; no. Supplement 1; p. 1811
• Main Authors: Cavazzini, Francesco, Capodanno, Isabella, Miggiano, Maria Cristina, Bucelli, Cristina, Leonetti Crescenzi, Sabrina, Russo, Sabina, Carmosino, Ida, Romano, Atelda, Sorà, Federica, Bonifacio, Massimiliano, Luciano, Luigiana, Caocci, Giovanni, Loglisci, Maria Pia, Elena, Chiara, Lunghi, Francesca, Mullai, Rikard, Attolico, Immacolata, Binotto, Gianni, Crisà, Elena, Sportoletti, Paolo, Di Veroli, Ambra, Scortechini, Anna Rita, Leporace, Anna Paola, Maggi, Alessandro, Crugnola, Monica, Stagno, Fabio, Santoro, Marco, Murgano, Pamela, Rapezzi, Davide, Luzi, Debora, Vincelli, Jolanda Donatella, Galimberti, Sara, Bocchia, Monica, Fava, Carmen, Malato, Alessandra, Abruzzese, Elisabetta, Saglio, Giuseppe, Specchia, Giorgina, Breccia, Massimo, Iurlo, Alessandra, Tiribelli, Mario, Latagliata, Roberto
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.11.2023

Introduction Median age at diagnosis in patients with Chronic Myeloid Leukemia (CML) is about 60 years: only few data are available in younger subjects at present. Aim To analyze initial features, choice of frontline Tyrosine-Kinase Inhibitor (TKI) and early adverse events leading to permanent TKI d...